资料显示，海思科医药集团股份有限公司位于西藏山南市泽当镇三湘大道17号，成立日期2005年8月26 日，上市日期2012年1月17日，公司主营业务涉及化学药品的研究开发、生产制造、销售推广。主营业 务收入构成为：麻醉产品39.81%，合作产品相关收入23.59%，其他适应症17.02%，肠外营养系 10.32%，肿瘤止吐8.15%，其他(补充)0.86%，其他主营业务收入0.26%。 11月25日，海思科盘中下跌2.02%，截至10:09，报57.81元/股，成交1.07亿元，换手率0.38%，总市值 647.42亿元。 资金流向方面，主力资金净流入606.14万元，特大单买入1833.28万元，占比17.17%，卖出1033.23万 元，占比9.68%；大单买入1271.38万元，占比11.91%，卖出1465.30万元，占比13.73%。 海思科今年以来股价涨75.29%，近5个交易日涨5.70%，近20日涨11.77%，近60日跌2.68%。 海思科所属申万行业为：医药生物-化学制药-化学制剂。所属概念板块包括：幽门螺杆概念、互联医 疗、高血压防治、生物医药、医疗器械等。 截至9月30日，海思科股东户数 ...

资料显示，海思科医药集团股份有限公司位于西藏山南市泽当镇三湘大道17号，成立日期2005年8月26 日，上市日期2012年1月17日，公司主营业务涉及化学药品的研究开发、生产制造、销售推广。主营业 务收入构成为：麻醉产品39.81%，合作产品相关收入23.59%，其他适应症17.02%，肠外营养系 10.32%，肿瘤止吐8.15%，其他(补充)0.86%，其他主营业务收入0.26%。 海思科所属申万行业为：医药生物-化学制药-化学制剂。所属概念板块包括：幽门螺杆概念、互联医 疗、高血压防治、生物医药、医疗器械等。 截至9月30日，海思科股东户数1.29万，较上期增加12.87%；人均流通股37342股，较上期减少11.40%。 2025年1月-9月，海思科实现营业收入33.00亿元，同比增长19.95%；归母净利润2.95亿元，同比减少 22.66%。 11月19日，海思科盘中上涨2.05%，截至11:04，报55.81元/股，成交5591.57万元，换手率0.21%，总市 值625.03亿元。 资金流向方面，主力资金净流入129.97万元，特大单买入397.04万元，占比7.10%，卖出125.79万元，占 ...

11月10日，海思科盘中上涨2.04%，截至14:26，报54.09元/股，成交1.23亿元，换手率0.48%，总市值 605.76亿元。 资金流向方面，主力资金净流出23.77万元，特大单买入127.86万元，占比1.04%，卖出0.00元，占比 0.00%；大单买入909.00万元，占比7.41%，卖出1060.63万元，占比8.65%。 海思科今年以来股价涨64.01%，近5个交易日跌2.96%，近20日涨6.69%，近60日跌9.03%。 资料显示，海思科医药集团股份有限公司位于西藏山南市泽当镇三湘大道17号，成立日期2005年8月26 日，上市日期2012年1月17日，公司主营业务涉及化学药品的研究开发、生产制造、销售推广。主营业 务收入构成为：麻醉产品39.81%，合作产品相关收入23.59%，其他适应症17.02%，肠外营养系 10.32%，肿瘤止吐8.15%，其他(补充)0.86%，其他主营业务收入0.26%。 海思科所属申万行业为：医药生物-化学制药-化学制剂。所属概念板块包括：幽门螺杆概念、高血压防 治、互联医疗、生物医药、创新药等。 截至9月30日，海思科股东户数1.29万，较上期增加1 ...

11月7日，海思科盘中下跌2.01%，截至09:54，报52.77元/股，成交2288.74万元，换手率0.09%，总市值 590.98亿元。 资金流向方面，主力资金净流出177.64万元，大单买入104.96万元，占比4.59%，卖出282.59万元，占比 12.35%。 海思科今年以来股价涨60.01%，近5个交易日跌6.85%，近20日涨2.25%，近60日跌6.75%。 分红方面，海思科A股上市后累计派现36.73亿元。近三年，累计派现6.87亿元。 机构持仓方面，截止2025年9月30日，海思科十大流通股东中，中欧医疗健康混合A（003095）位居第 五大流通股东，持股2139.75万股，相比上期增加12.12万股。香港中央结算有限公司位居第六大流通股 东，持股1806.01万股，相比上期增加988.04万股。工银前沿医疗股票A（001717）位居第七大流通股 东，持股1560.01万股，相比上期增加50.00万股。汇添富创新医药混合A（006113）位居第八大流通股 东，持股1305.57万股，相比上期增加62.90万股。富国精准医疗灵活配置混合A（005176）位居第九大 流通股东，持股806. ...

Core Viewpoint - The stock of Haishike experienced a decline of 2.20% on October 29, 2023, with a current price of 50.58 yuan per share, reflecting a total market capitalization of 566.45 billion yuan. Despite a year-to-date increase of 53.37%, the stock has seen a downward trend in recent trading days [1][2]. Financial Performance - For the period from January to September 2025, Haishike reported a revenue of 3.3 billion yuan, representing a year-on-year growth of 19.95%. However, the net profit attributable to shareholders decreased by 22.66% to 295 million yuan [2]. - Cumulatively, Haishike has distributed 3.673 billion yuan in dividends since its A-share listing, with 687 million yuan distributed over the past three years [3]. Shareholder Information - As of September 30, 2025, the number of shareholders increased by 12.87% to 12,900, with an average of 37,342 circulating shares per shareholder, down by 11.40% from the previous period [2]. - The top ten circulating shareholders include various funds, with notable increases in holdings from several institutional investors, such as China Europe Medical Health Mixed A and Hong Kong Central Clearing Limited [3]. Business Overview - Haishike, established on August 26, 2005, and listed on January 17, 2012, specializes in the research, development, production, and sales of chemical pharmaceuticals. The main revenue sources include anesthetic products (39.81%), cooperative product-related income (23.59%), and other therapeutic areas [1]. - The company operates within the pharmaceutical and biotechnology sector, specifically in chemical pharmaceuticals and formulations, and is involved in various concept sectors such as hypertension treatment and innovative drugs [1].

Core Viewpoint - Haikang's stock price has shown a continuous upward trend, reflecting positive market sentiment and potential investment opportunities in the pharmaceutical sector [1][2]. Company Overview - Haikang Pharmaceutical Group Co., Ltd. was established on August 26, 2005, and went public on January 17, 2012. The company is located in Zedang Town, Shannan City, Tibet [1]. - The main business activities include research and development, manufacturing, and sales of chemical drugs [1]. - Revenue composition is as follows: anesthetic products 39.81%, cooperative product-related income 23.59%, other indications 17.02%, parenteral nutrition 10.32%, antiemetics for tumors 8.15%, and other supplementary income 0.86% [1]. Stock Performance - As of October 17, Haikang's stock price increased by 0.75% to 52.50 CNY per share, with a trading volume of 227 million CNY and a turnover rate of 0.89%. The total market capitalization is 58.796 billion CNY [1]. - The stock has risen for three consecutive days, with a cumulative increase of 6.49% during this period [1]. Fund Holdings - Southern Fund's Southern Medical Health Flexible Allocation Mixed A (000452) holds a significant position in Haikang, with 3.9138 million shares, unchanged from the previous period, accounting for 6.84% of the fund's net value [2]. - The fund has realized a floating profit of approximately 1.5264 million CNY today and 12.5241 million CNY during the three-day upward trend [2]. - The fund was established on January 23, 2014, with a current scale of 2.405 billion CNY and has achieved a year-to-date return of 45.86% [2].

分红方面，海思科A股上市后累计派现36.73亿元。近三年，累计派现6.87亿元。 机构持仓方面，截止2025年6月30日，海思科十大流通股东中，中欧医疗健康混合A（003095）位居第 五大流通股东，持股2127.63万股，相比上期增加535.74万股。工银前沿医疗股票A（001717）位居第六 大流通股东，持股1510.01万股，相比上期增加540.00万股。汇添富创新医药混合A（006113）位居第七 大流通股东，持股1242.67万股，相比上期增加267.25万股。富国精准医疗灵活配置混合A（005176）位 居第八大流通股东，持股937.79万股，相比上期减少191.01万股。汇添富医疗服务灵活配置混合A （001417）位居第九大流通股东，持股875.93万股，相比上期减少170.31万股。香港中央结算有限公司 位居第十大流通股东，持股817.97万股，为新进股东。 责任编辑：小浪快报 资料显示，海思科医药集团股份有限公司位于西藏山南市泽当镇三湘大道17号，成立日期2005年8月26 日，上市日期2012年1月17日，公司主营业务涉及化学药品的研究开发、生产制造、销售推广。主营业 务收入构成为：麻醉 ...

10月15日，海思科涨5.03%，截至发稿，报51.78元/股，成交9643.00万元，换手率0.39%，总市值579.89 亿元。 中信建投医改A（002408）成立日期2016年4月6日，最新规模6.03亿。今年以来收益26.89%，同类排名 3036/8161；近一年收益15.85%，同类排名4467/8015；成立以来收益86.51%。 中信建投医改A（002408）基金经理为谢玮。 截至发稿，谢玮累计任职时间7年135天，现任基金资产总规模19.87亿元，任职期间最佳基金回报 90.48%， 任职期间最差基金回报-26.44%。 资料显示，海思科医药集团股份有限公司位于西藏山南市泽当镇三湘大道17号，成立日期2005年8月26 日，上市日期2012年1月17日，公司主营业务涉及化学药品的研究开发、生产制造、销售推广。主营业 务收入构成为：麻醉产品39.81%，合作产品相关收入23.59%，其他适应症17.02%，肠外营养系 10.32%，肿瘤止吐8.15%，其他(补充)0.86%，其他主营业务收入0.26%。 从基金十大重仓股角度 数据显示，中信建投基金旗下1只基金重仓海思科。中信建投医改A（002 ...

Core Viewpoint - The stock of Haisco Pharmaceutical Group Co., Ltd. has experienced fluctuations, with a year-to-date increase of 53.27% but a recent decline in the last five and twenty trading days [1][2]. Financial Performance - For the first half of 2025, Haisco achieved a revenue of 2 billion yuan, representing a year-on-year growth of 18.63%, while the net profit attributable to shareholders decreased by 21.79% to 129 million yuan [2]. - Cumulatively, Haisco has distributed 3.673 billion yuan in dividends since its A-share listing, with 687 million yuan distributed over the past three years [3]. Shareholder Structure - As of June 30, 2025, the number of Haisco's shareholders increased by 25.93% to 11,400, while the average circulating shares per person decreased by 28.64% to 42,147 shares [2]. - The top ten circulating shareholders include several funds, with notable increases in holdings from China Europe Medical Health Mixed A and ICBC Frontier Medical Stock A [3]. Stock Market Activity - On October 13, Haisco's stock price fell by 2.05% to 50.55 yuan per share, with a trading volume of approximately 54.66 million yuan and a turnover rate of 0.22% [1]. - The stock's market capitalization stands at 56.612 billion yuan, with a net inflow of main funds amounting to 2.05 million yuan [1].

Group 1 - The core viewpoint of the news highlights the recent performance and financial metrics of Haishike Pharmaceutical Group, including stock price movements and market capitalization [1][2] - As of September 25, Haishike's stock price increased by 2.07% to 56.17 CNY per share, with a total market capitalization of 629.06 billion CNY [1] - Year-to-date, Haishike's stock has risen by 70.32%, with a 2.59% increase over the last five trading days and a 27.57% increase over the last 60 days [1] Group 2 - For the first half of 2025, Haishike reported a revenue of 2.001 billion CNY, representing a year-on-year growth of 18.63%, while the net profit attributable to shareholders decreased by 21.79% to 129 million CNY [2] - The company has distributed a total of 3.673 billion CNY in dividends since its A-share listing, with 687 million CNY distributed over the last three years [3] - As of June 30, 2025, the number of Haishike's shareholders increased by 25.93% to 11,400, while the average number of circulating shares per shareholder decreased by 28.64% to 42,147 shares [2][3] Group 3 - Haishike's main business segments include anesthetic products (39.81%), cooperative product-related income (23.59%), and other therapeutic areas [1] - The company is classified under the pharmaceutical and biological industry, specifically in chemical pharmaceuticals and preparations, with involvement in various concept sectors such as Helicobacter pylori, hypertension treatment, and innovative drugs [1] - Notable institutional shareholders include China Europe Medical Health Mixed Fund and ICBC Frontier Medical Stock Fund, with significant increases in their holdings [3]